Angiotensin II receptor antagonists

@article{Burnier2000AngiotensinIR,
  title={Angiotensin II receptor antagonists},
  author={Michel Burnier and H. R. Brunner},
  journal={The Lancet},
  year={2000},
  volume={355},
  pages={637-645}
}
Blockade of the renin-angiotensin system began as a way of studying the pathogenesis of cardiovascular disease with specific pharmacological probes. Oral activity, achieved by shortening the original peptide structures, transformed the probes into therapeutic agents, the angiotensin-converting enzyme (ACE) inhibitors. However, ACE is a non-specific target for blocking the renin-angiotensin enzymatic cascade. The availability of orally active drugs turned ACE inhibition into a therapeutic… Expand
Angiotensin II receptor antagonists in hypertension.
TLDR
Two new molecules are as effective as ACE inhibitors, calcium antagonists and beta-blockers in lowering blood pressure in hypertensive patients and appear to have comparable favorable effects on systemic and renal hemodynamic properties. Expand
ANGIOTENSIN II RECEPTOR BLOCKERS : AN OVERVIEW Review Article
Blockage of the renin-angiotensin system (RAS) is now recognized as an effective approach to the treatment of hypertension and congestive heart failure. Today, it is possible to antagonize theExpand
Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations
  • H. Siragy
  • Medicine
  • Cardiovascular Drugs and Therapy
  • 2010
TLDR
In this review, recent clinically relevant advances in the understanding of renin-angiotensin system biology are explored as a rationale for combining aliskiren with other blockers of the renin, with the goal of providing additional therapeutic benefits in diseases associated with chronic activated renin. Expand
An update on non-peptide angiotensin receptor antagonists and related RAAS modulators.
TLDR
A series of low molecular weight nonpeptide imidazole analogues that possess weak but selective, competitive AT1 receptor blocking property are developed that cause a more complete RAAS blockade than ACE inhibitors. Expand
Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
TLDR
By blocking Ang II at the AT1 receptor level, Ang II receptor blockers (ARBs) provide a more specific and complete blockade of the deleterious effects of Ang II and tend to have more favourable tolerability. Expand
Clinical Evidence for the Cardiovascular Benefits of Angiotensin Receptor Blockers
Targeting the renin-angiotensin-aldosterone system (RAAS), specifically the effector peptide angiotensin II (Ang II), represents a major opportunity for slowing the progression of cardiovascularExpand
Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
  • C. Ram
  • Medicine
  • Future cardiology
  • 2009
TLDR
The first-in-class direct renin inhibitor, aliskiren, blocks the RAAS at its point-of-activation, suppressing PRA and attenuating increases associated with other antihypertensives. Expand
Oral renin inhibitors in clinical practice: a perspective review
TLDR
Clinical trials and in vitro studies suggest that aliskiren reduces baseline systolic and diastolic blood pressure greater than placebo and that it is as effective as other first-line antihypertensive agents. Expand
Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
TLDR
What is presently known about ACEI/ARB combination therapy is examined and alternative combination strategies that include DRIs and mineralocorticoid receptor blockers (MRBs) are explored. Expand
Angiotensin II subtype 1 receptor blockers and renal function.
  • R. Toto
  • Medicine
  • Archives of internal medicine
  • 2001
TLDR
The role of ARBs in patients with hypertension and type 2 diabetes is being evaluated in 3 large trials, including Appropriate Blood Pressure Control in Diabetes-Part 2 With Valsartan, the Losartan Renal Protection Study, and the Irbesartan Diabetic Nephropathy Trial. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 115 REFERENCES
Human renin inhibitor peptides.
TLDR
It could be anticipated that potent and specific renin inhibitors would constitute an interesting alternative to ACEI for two reasons: 1) the first step in the renin-angiotensin system, the hydrolysis of ang Elliotensinogen by renin, is rate limiting; and 2) renin has a unique specificity for angiotens inogen as there is no other known substrate for this enzyme. Expand
AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions.
TLDR
Clinical experience in general practice is extensive and AT1-receptor blockers have been prescribed to several million patients, and the question of whether clinically relevant differences might exist is raised. Expand
AT 1-receptor blockers in hypertension and heart failure : clinical experience and future directions
In various manifestations of cardiovascular disease, blockade of the renin–angiotensin system by angiotensin converting enzyme (ACE) inhibitors has been shown to prevent or delay disease progressionExpand
Comparative Safety and Tolerability of Angiotensin II Receptor Antagonists
TLDR
If angiotensin II receptor antagonists prevent target organ damage and reduce the morbidity and mortality of patients with hypertension, they may well become a first-line treatment of hypertension. Expand
Renal effects of angiotensin II receptor blockade in normotensive subjects.
TLDR
In normotensive subjects, losartan and irbesartan have been shown to have no effect on glomerular filtration rate and to induce either no change or a modest increase in renal blood flow, and this property is shown to be due to the potent inhibitory effect of the parent compound ofLosartan on the urate/anion transport in the human renal proximal tubule. Expand
Clinical pharmacology of ACE inhibition.
TLDR
Any discussion of whether tissue or plasma renin determines the pharmacologic effect of ACE inhibitors should be based on the simultaneous measurement of angiotensin-(1-8)octapeptide under steady-state conditions in tissue and plasma. Expand
Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?
TLDR
The effects of specific intervention in the renin-angiotensin system with the Ang II receptor antagonist losartan and enalapril were investigated and compared these effects to those obtained with ACE inhibition, as this comparison might resolve the question whether or not the effects of ACE inhibition are Ang II related. Expand
Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
TLDR
It is demonstrated that the first administration of the recommended starting dose of irbesartan induces a greater and longer lasting Ang II receptor blockade than that of valsartan and losartan in normotensive subjects. Expand
Angiotensin receptor antagonists in experimental models of chronic renal failure.
TLDR
It may be premature to conclude that ACEI and AT1RA are, essentially, therapeutically equivalent, since both classes of drug have such potent renoprotective effects, and the extent of injury that develops in treated rats may be so slight as to compromise the sensitivity of the experimental comparison. Expand
Pharmacology of valsartan, an angiotensin II receptor antagonist.
TLDR
Three large clinical trials are now underway to demonstrate whether valsartan can reduce morbidity and mortality: one in hypertensives with a high cardiovascular risk profile (VALUE), one in patients with heart failure previously treated with an angiotensin-converting enzyme inhibitor (VAL-HeFT) and one in post-myocardial infarct patients (VALIANT). Expand
...
1
2
3
4
5
...